Dallah Healthcare Co.

As of June 30, 2026, Dallah Healthcare Co. carries a market capitalization of 9.26B, placing it among publicly traded companies globally. Its enterprise value stands at 13.43B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Dallah Healthcare Co.'s next confirmed earnings release is scheduled for November 9, 2026.

As of June 30, 2026, Dallah Healthcare Co. has 101.20M shares outstanding.

As of June 30, 2026, Dallah Healthcare Co. trades at a trailing price-to-earnings ratio of 21.92. The price-to-sales ratio is 2.26, and the price-to-book ratio stands at 2.24.

As of June 30, 2026, Dallah Healthcare Co. trades at an EV/EBITDA multiple of 19.86 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.13 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 31.03 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Dallah Healthcare Co. trades at an EV/FCF ratio of 138.14, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 13.43B versus a market cap of 9.26B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Dallah Healthcare Co. maintains a current ratio of 1.21, meaning it holds 1.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 101.69, indicating elevated leverage, while an interest coverage ratio of 3.94 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Dallah Healthcare Co. posted a return on equity (ROE) of 10.72, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.24 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 4.83, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 7.56, useful for judging operating efficiency across full business cycles. Inventory turnover of 7.24 indicates how many times Dallah Healthcare Co. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Dallah Healthcare Co. recorded 18.91M in income tax expense. That works out to an effective tax rate of 4.10, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 460.87M, leaving 442.98M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Dallah Healthcare Co.'s stock has declined approximately 49.54% over the past 52 weeks. The 50-day moving average sits at 78.79, while the 200-day moving average is 91.96.

Over the twelve months ended June 30, 2026, Dallah Healthcare Co. generated 4.29B in revenue and converted that into 442.98M in net income, yielding earnings per share of 4.16. EBITDA reached 676.34M, while operating income came in at 541.53M.

As of June 30, 2026, Dallah Healthcare Co. holds 87.85M in cash and equivalents against 4.23B in total debt, resulting in a net debt position of 3.99B. Total book value stands at 4.13B, with working capital of 409.10M providing operational flexibility.

Dallah Healthcare Co. produced 417.86M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -485.24M in capital expenditures, free cash flow totaled -67.38M - equivalent to -0.63 per share.

Over the twelve months ended June 30, 2026, Dallah Healthcare Co. posted a gross margin of 34.95, reflecting its pricing power and cost economics. The operating margin of 12.61 and net profit margin of 10.32 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Dallah Healthcare Co. paid dividends of 0.98 per share. The dividend payout ratio of 23.65 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -0.69: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.35, meaning Dallah Healthcare Co. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dallah Healthcare Co.'s most recent stock split took place on August 31, 2026 with a 5:6 split ratio.

As of June 30, 2026, Dallah Healthcare Co. has an Altman Z-Score of 2.03, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.